We investigated the changes in and characteristics of renal function in Japanese patients with high-risk prostate cancer (PCa) who underwent radiotherapy and long-term androgen deprivation therapy (ADT), including those seen after the ADT was discontinued.
Cancers with mutations in BRCA2 have defective DNA repair capacity which is potentially targetable with poly-ADP(ribose) polymera se (PARP) inhibitors such as olaparib and rucaparib. However, the development of a secondary mutation that restores BRCA2 function is a well-documented mechanism of resistance to PARP inhibitors.
To analyze the association between salivary melatonin rhythm and prostate cancer (PCa). A total of 40 PCa cases and 41 controls from CAPLIFE study were analyzed to determine the salivary melatonin rhythm through 6 saliva samples.
Genome-wide association studies (GWASs) of prostate cancer have identified >250 significant risk loci, but the causal variants and mechanisms for these loci remain largely unknown. Here, we sought to identify and characterize risk-harboring regulatory elements by integrating epigenomes from primary prostate tumor and normal tissues of 27 individuals across the H3K27ac, H3K4me3, and H3K4me2 histone […]
Docetaxel has been widely used in metastatic Castration-resistant Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate the efficacy of docetaxel rechallenge in patients with mCRPC.
Squamous cell carcinoma (SCC) of the penis is rare. Some studies have suggested that the incidence is increasing but the available literature is equivocal. We examined the incidence of high-grade penile intraepithelial neoplasia (PeIN), the incidence and 5-year relative survival as well as mortality of penile SCC in Denmark over the latest 20 years.
The purpose of this review is to describe the causes, management, and clinical outcomes associated with cachexia and related components including sarcopenia, among patients with bladder cancer (BCa).
Intrinsic molecular subtypes may explain marked variation between bladder cancer patients in prognosis and response to therapy. Complex testing algorithms and little attention to more prevalent, early-stage (non-muscle invasive) bladder cancers (NMIBCs) have hindered implementation of subtyping in clinical practice.
Alicia Morgans: Hi. My name is Alicia Morgans, and I am a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston, in the US. I am so excited to have here with me today, a good friend and colleague, Dr. Elena Castro, who is a GU Medical Oncologist at the Institute of Biomedical Research of […]
Alicia Morgans: Hi, and welcome back to Clinical Case-Based Learning. We are still talking about a virtual tumor board in advanced prostate cancer. And this is case number four, Mr. Elijah Lewis, and he has a prostate cancer recurrence. Mr. Lewis is a 70-year-old man with no past medical history other than locally advanced prostate […]
